MetaCap

Heron Therapeutics Inc. (HRTX)

NASDAQ: HRTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.2525-0.0116 (-4.39%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

HRTX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$48.04M
EPS (TTM)
-$0.11
52-week range
0.2479 – 1.58
Day range
0.2479 – 0.2695
Volume / Avg
1.75M / 4.56M
Beta
—

52-week range

$0.2479$1.58

HRTX stock today

Heron Therapeutics (HRTX) closed at $0.2525 on Nov 20, down 4.39% (-$0.0116), versus the S&P 500's 3.70% decline. Trading was light, with 1.75M shares changing hands, about 38% of the average daily volume. At this level, HRTX sits near the bottom of its 52-week range of $0.2479 to $1.58: 84.0% below the high, set on Jan 9, 2026 and 1.9% above the low.

HRTX is down 80.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 76.2%. Heron Therapeutics has posted a net loss over the last twelve months (EPS of -$0.11), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Heron Therapeutics

Company profile

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Craig Alexander Collard
Headquarters
Cary, NC
Employees
128

Financial highlights

Full financials

In fiscal 2025, Heron Therapeutics generated $154.9 million in revenue, up 7.4% from fiscal 2024, its 4th consecutive year of revenue growth. Heron Therapeutics reported a net loss of $20.2 million, compared with a loss of $13.6 million a year earlier. Gross margin was 73.3% (up from 73.2%) and operating margin -1.6%.

Heron Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$154.90M$144.28M$127.04M$107.67M$86.35M
Growth+7.36%+13.57%+17.99%+24.70%-2.59%
Net income$-20.20M$-13.58M$-110.56M$-182.02M$-220.68M
EPS (diluted)$-0.12$-0.09$-0.80$-1.67$-2.24

Analyst forecast

Forecast

Consensus (2 analysts)

none

Avg. price target

$7.00+2672.28%

  • Strong buy 0
  • Buy 0
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $5.00High $9.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.05 vs $-0.03
Surprise
-66.67%

HRTX news

All HRTX news

Heron Therapeutics peers

Health Care sector
HRTX peer companies
CompanyPrice% ChgMarket capCompare
RFLRafael Holdings Inc. Class B0.9197+2.19%$47.99Mvs HRTX
ONCYOncolytics Biotech Inc.0.3501-10.37%$47.66Mvs HRTX
NMADNomad Power Solutions Inc.2.56+13.53%$47.15Mvs HRTX
VRCAVerrica Pharmaceuticals Inc.2.74-5.03%$47.07Mvs HRTX
ACRVAcrivon Therapeutics Inc.1.15-17.86%$49.35Mvs HRTX
TNXPTonix Pharmaceuticals Holding Corp.2.38-6.67%$46.25Mvs HRTX
MISTMilestone Pharmaceuticals Inc.0.3711-7.06%$46.20Mvs HRTX
HOWLWerewolf Therapeutics Inc.0.9466-3.97%$46.00Mvs HRTX

Indexes, lists and sector

Heron Therapeutics stock FAQ

What is Heron Therapeutics's stock price today?

HRTX last traded at $0.2525 as of Nov 20, 4:00 PM EST, down 4.39% on the day. Prices are delayed at least 15 minutes.

Does Heron Therapeutics pay a dividend?

No. Heron Therapeutics does not currently pay a regular cash dividend.

Who is Heron Therapeutics's CEO?

Mr. Craig Alexander Collard is the chief executive officer of Heron Therapeutics Inc., which has about 128 employees.

Has HRTX ever split its stock?

Yes. The most recent HRTX stock split was a 1-for-20 split on Jan 13, 2014, one of 2 splits on record.

What is the HRTX 52-week high?

The 52-week high for HRTX is $1.58 and the 52-week low is $0.2479. The stock is currently 84.0% below its high.

Compare HRTX